These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37462865)

  • 1. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.
    Zhang B; Zhao R; Wang Q; Zhang YJ; Yang L; Yuan ZJ; Yang J; Wang QJ; Yao L
    Adv Ther; 2023 Oct; 40(10):4339-4357. PubMed ID: 37462865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
    Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
    Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
    Zhang J; Zhang M; Tian Q; Yang J
    Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
    Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
    Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
    Yang X; Tang W; He Y; An H; Wang J
    Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments.
    Zhang M; Zhang F; Wang J; Liang Q; Zhou W; Liu J
    J Transl Med; 2024 May; 22(1):423. PubMed ID: 38704606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An EMT-related genes signature as a prognostic biomarker for patients with endometrial cancer.
    Yu Y; Zhang Y; Li Z; Dong Y; Huang H; Yang B; Zhao E; Chen Y; Yang L; Lu J; Qiu F
    BMC Cancer; 2023 Sep; 23(1):879. PubMed ID: 37723477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
    Liu Z; Ding M; Qiu P; Pan K; Guo Q
    Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
    Shen X; Zhong J; He J; Han J; Chen N
    Front Immunol; 2022; 13():978092. PubMed ID: 36105819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
    Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
    Front Immunol; 2021; 12():805883. PubMed ID: 35095892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.
    Hu Y; Zou D
    PLoS One; 2021; 16(12):e0260811. PubMed ID: 34965257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer.
    Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G
    Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.
    Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H
    Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
    Yan C; Liu Q; Jia R
    Front Oncol; 2022; 12():829045. PubMed ID: 35186763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomics and prognosis analysis of epithelial-mesenchymal transition in colorectal cancer patients.
    Zhang Z; Zheng S; Lin Y; Sun J; Ding N; Chen J; Zhong J; Shi L; Xue M
    BMC Cancer; 2020 Nov; 20(1):1135. PubMed ID: 33228590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
    Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
    Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
    Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.